Delcath Systems (NASDAQ:DCTH – Get Free Report) is set to release its earnings data after the market closes on Monday, November 13th. Analysts expect Delcath Systems to post earnings of ($0.50) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
Delcath Systems (NASDAQ:DCTH – Get Free Report) last issued its earnings results on Wednesday, August 9th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.09. The business had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.73 million. On average, analysts expect Delcath Systems to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Delcath Systems Stock Down 1.3 %
Shares of DCTH opened at $2.95 on Friday. The stock has a fifty day simple moving average of $3.85 and a two-hundred day simple moving average of $5.04. The company has a market capitalization of $45.08 million, a PE ratio of -0.94 and a beta of 0.51. Delcath Systems has a 52-week low of $2.76 and a 52-week high of $7.99.
Wall Street Analysts Forecast Growth
Insider Transactions at Delcath Systems
In other news, COO John Purpura purchased 14,505 shares of the firm’s stock in a transaction dated Friday, October 13th. The shares were acquired at an average price of $3.44 per share, with a total value of $49,897.20. Following the purchase, the chief operating officer now directly owns 41,526 shares of the company’s stock, valued at $142,849.44. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Delcath Systems news, Director John Richard Sylvester purchased 10,550 shares of the stock in a transaction on Monday, August 21st. The stock was bought at an average price of $4.80 per share, for a total transaction of $50,640.00. Following the acquisition, the director now directly owns 10,550 shares of the company’s stock, valued at $50,640. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO John Purpura purchased 14,505 shares of the firm’s stock in a transaction on Friday, October 13th. The stock was bought at an average price of $3.44 per share, for a total transaction of $49,897.20. Following the acquisition, the chief operating officer now owns 41,526 shares in the company, valued at $142,849.44. The disclosure for this purchase can be found here. Company insiders own 21.10% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Delcath Systems by 5.7% during the first quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock worth $2,309,000 after purchasing an additional 19,605 shares in the last quarter. Geode Capital Management LLC grew its stake in Delcath Systems by 85.8% during the 2nd quarter. Geode Capital Management LLC now owns 116,536 shares of the company’s stock valued at $679,000 after acquiring an additional 53,803 shares in the last quarter. Cibc World Market Inc. increased its stake in Delcath Systems by 4.0% in the 1st quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after buying an additional 3,432 shares during the period. BlackRock Inc. lifted its holdings in shares of Delcath Systems by 183.7% during the 2nd quarter. BlackRock Inc. now owns 47,180 shares of the company’s stock valued at $275,000 after buying an additional 30,548 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in Delcath Systems by 77.7% in the second quarter. Renaissance Technologies LLC now owns 21,500 shares of the company’s stock worth $125,000 after buying an additional 9,400 shares during the last quarter. 85.15% of the stock is owned by institutional investors and hedge funds.
Delcath Systems Company Profile
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Five stocks we like better than Delcath Systems
- Energy and Oil Stocks Explained
- Data giants MongoDB and Snowflake just got upgraded
- What is the S&P 500 and How It is Distinct from Other Indexes
- Plug Power at tipping point; it’s make or break time for hydrogen
- How to Invest and Trade Chinese Stocks
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.